2.14 - Peptide and Protein Drugs: Issues and Solutions
References (0)
Cited by (0)
John J Nestor, Jr, PhD – CSO, Founding CEO; TheraPei Pharmaceuticals, Inc., has more than 25 years of pharmaceutical industry experience in drug discovery and scientific management, much of that time at the VP level in major pharma. He is co-inventor of 10 compounds selected for clinical development, including three that are now marketed drugs (Synarel, Antagon, Valcyte).
Prior to founding TheraPei Pharmaceuticals, John was Executive Vice President, Drug Discovery at Sequenom, leading the target validation and drug discovery groups. Prior to joining Sequenom, he served as President and Chief Scientific Officer at Consensus Pharmaceuticals. John was Vice President, Syntex Discovery Research and Director of the Institute of Bio-Organic Chemistry. Following the acquisition of Syntex by Roche, he served as Distinguished Scientist in the Roche Bioscience organization, until co-founding a chemistry-focused, drug discovery company, Helios Pharmaceuticals.
John obtained his BS in chemistry from the Polytechnic Institute of Brooklyn and a PhD in organic chemistry from the University of Arizona. After post-doctoral research at Cornell University with the Nobelist, Prof Vincent du Vigneaud, Dr Nestor joined Syntex Research to initiate peptide drug discovery. Dr Nestor is co-inventor of more than 40 issued US patents, author of more than 60 scientific articles, co-editor of 2 books. He also is an Associate Editor of the journal Letters in Drug Design and Discovery and on the Editorial Advisory Boards of Current Medicinal Chemistry and Medicinal Chemistry (Bentham Publishers).